Evidence that a novel dopamine receptor agonist, RDS‐127 [2−di‐n‐propylamino−4,7−dimethoxyindane] has some centrally mediated cardiovascular actions† †

@article{Arneric1984EvidenceTA,
  title={Evidence that a novel dopamine receptor agonist, RDS‐127 [2−di‐n‐propylamino−4,7−dimethoxyindane] has some centrally mediated cardiovascular actions† †},
  author={S. Arneric and J. Long},
  journal={Journal of Pharmacy and Pharmacology},
  year={1984},
  volume={36}
}
  • S. Arneric, J. Long
  • Published 1984
  • Medicine
  • Journal of Pharmacy and Pharmacology
  • The cardiovascular effects of RDS−127 [2−di‐n‐propylamino−4,7−dimethoxyindane] were examined in normotensive, anaesthetized rats. RDS−127 given i.v. (12·5–125 μ kg−1) produced dose‐dependent bradycardia. The bradycardic effect was 20·5 times more potent when the drug was administered intracerebroventricularly (i.c.v.) than when given i.v. RDS−127 produced a slight, but significant hypotension. Haloperidol given i.c.v. or i.v. reversed these bradycardic and hypotensive actions, whereas… CONTINUE READING
    2 Citations

    Topics from this paper.

    Dopamine agonists: structure-activity relationships.
    • J. Cannon
    • Chemistry, Medicine
    • Progress in drug research. Fortschritte der Arzneimittelforschung. Progres des recherches pharmaceutiques
    • 1985
    • 42

    References

    SHOWING 1-10 OF 13 REFERENCES
    RDS-127 (2-di-n-propylamino-4,7-dimethoxyindane): central effects of a new dopamine receptor agonist.
    • 31
    Inhibition of the sympathetic nervous system by 5,6-dihydroxy-2-dimethylamino tetralin (M-7), apomorphine and dopamine.
    • 90
    The cardiovascular effects of apomorphine in the anaesthetized rat.
    • 28
    Vasodilatation produced by apomorphine in the hindleg of the dog.
    • 30